| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Sage Therapeutics Inc. | SAGE-324 (BIIB124) - (KINETIC 2) | Essential tremor | Phase 2b | Trial Discontinued | Oral | Neurology |
| Sage Therapeutics Inc. | Dalzanemdor (SAGE-718) - (DIMENSION) | Huntington's disease (HD) | Phase 2 | Data Released | Oral | Neurology |
| Sage Therapeutics Inc. | Dalzanemdor (SAGE-718) - (LIGHTWAVE) | Mild cognitive impairment and mild dementia due to AD | Phase 2 | Data Released | Oral | Neurology |
| Sage Therapeutics Inc. | Dalzanemdor (SAGE-718) - (PRECEDENT) | Mild cognitive impairment (MCI) | Phase 2 | Trial Discontinued | oral | Neurology |
| Sage Therapeutics Inc. | SAGE-718 - (SURVEYOR) | Huntington's disease | Phase 2 | Data Released | oral | Neurology |
| Sage Therapeutics Inc. | SAGE-217 - ARCHWAY | Bipolar depression | Phase 2 | Trial Completed | Oral | Psychiatric |
| Sage Therapeutics Inc. | SAGE-718 (718-CNA-201) - (LUMINARY) | Alzheimer’s disease (AD) cognitive dysfunction and mild dementia | Phase 2a | Ongoing | Oral | Neurology |
| Sage Therapeutics Inc. | SAGE-718 - (PARADIGM) | Parkinson Disease | Phase 2a | Trial Completed | Oral | Neurology |